Sentiment Trading

Biogen Inc. has initiated a global Phase 3 clinical study, PROMINENT, to evaluate the efficacy and safety of felzartamab in treating primary membranous nephropathy, a rare kidney disease.

Biogen Inc.’s stock price has declined significantly from its 52-week high of $238 to $126.30, reflecting broader market dynamics and investor sentiment.

Biogen Inc. reported strong Q1 2025 performance with $2.43 billion in revenue, driven by demand for its rare disease therapies, despite lowering its full-year earnings guidance.